Biotech

All Articles

OS Treatments refiles $6M IPO to money HER2 drug, preclinical ADCs

.Operating system Therapies will definitely specify on the NYSE American sell swap this morning by m...

ALX's fizzling CD47 feedback cost sends stock spiraling down

.ALX Oncology's phase 2 stomach cancer feedback price has actually weakened. After observing its own...

Ionis centers eye condition from aim ats of Roche-partnered possibility after information dissatisfy

.One More of Ionis Pharmaceuticals' crucial midphase readouts has disappointed requirements, motivat...

Biogen's chief executive officer mentioned no dangerous handle 2023. He's ready to become strong

.While Biogen's pharma peers are actually looking for late-stage assets with little risk, chief exec...

Instil refills pipeline in $2B biobucks take care of ImmunOnco

.Instil Biography has actually been a biotech looking for a pipe after it scrapped its own lead reso...

Biogen walks away from Denali Alzheimer's collab

.Biogen has actually handed back rights to an early Alzheimer's disease system to Denali Therapies, ...

Takeda taps brand-new mind people oncology service-- Chutes &amp Ladders

.Invite to recently's Chutes &amp Ladders, our roundup of significant leadership hirings, shootings ...

Vertex, beaten through AATD again, falls 2 assets on throw out stack

.Tip's effort to manage an unusual hereditary condition has reached one more problem. The biotech to...

Vir gains 3 T-cell engagers from Sanofi, gives up 25% of team

.Vir Biotechnology's second-quarter revenues report wasn't except large updates. The provider welcom...

Galapagos stops briefly CAR-T tissue treatment trial over Parkinsonism situation

.Galapagos has stopped enrollment in a trial of a BCMA-directed CAR-T cell treatment, pushing the br...